Abstract:OBJECTIVE:To investigate the expression of CD19 on childhood acute leukemia (AL) and its significance, and to provide evidence for the diagnosis and differential diagnosis as well as monoclonal antibody-targeting treatment of leukemia.METHODS:There were 210 cases of childhood AL, of which 130 cases were male and 80 were female with a mean age of 9 years old. Using a panel of 27 fluorochrome directly labeled monoclonal antibodies, 210 samples from the patients were analyzed with CD45/SSC double parameters and multi-color flow cytometry to determine the expression of CD19.RESULTS:In the 93 cases of B lineage acute lymphoblastic leukemia (ALL), the positive rate (98.9%, 92/93) of CD19 was significantly higher than that of the other B cell related antigens, such as CD10 (88.2%, 82/93, P = 0.003), CD20 (24.7%, 23/93, P = 0.001) and CD22 (60.2%, 56/93, P = 0.001). CD19 was expressed on all 8 cases of B/myeloid (My) hybrid acute leukemia (HAL) and 1 case of B/T HAL, but was not expressed on all 24 cases of T lineage leukemia and 5 cases of T/My HAL. In the 79 cases of acute myeloid leukemia (AML), only 5 (6.3%) cases expressed CD19. The positive rate (6.3%) of CD19 on AML was significantly lower than that on B lineage ALL (98.9%, P = 0.001). The percentage of CD19 positive cells in B/My HAL (41.6% - 88.7% with a mean of 73.8%) was significant higher than that in CD19(+)-AML (21.4% - 50.4% with a mean of 24.2%; Run Sum test, P = 0.0084). Of the 210 cases, 102 were B lineage related AL including B lineage ALL, B/My HAL and B/T HAL. In B lineage related AL, the sensitivity and the specificity of CD19 was 99.0% (101/102) and 95.4% (13/108) while the positive predictive and the negative predictive values to B lineage were 95.3% (101/106) and 99.0% (103/104), respectively. Using CD19(+) as a single reagent to diagnose B lineage, the false positive rate was 4.6% (5/108) and the false negative rate was 1.0% (1/102) with a general diagnosis index (GDI) of 94.4% [GDI = 1-(false positive rate + false negative rate)].CONCLUSION:CD19 is continuously and stably expressed on all stages of B lineage differentiation. It is a reliable cell membrane marker for diagnosing B lineage ALL and an ideal target for antibody-targeting treatment of leukemia as well; the expression degree of CD19 can be used to distinguish B/My HAL from CD19(+)-AML; CD19 didn't express on normal myeloid cells but did on some AML cells. Therefore it can be used to detect the minimal residual disease.

Expression and significance of B cell-specific activator protein (Pax-5) in lymphomas

[Expression of B Cell-Specific Activator Protein in Lymphomas].

Pax5 Expression in Non-Hodgkin's Lymphomas and Acute Leukemias.

[Prognostic Significance of Proteins Expression by Immunohistochemical Method in Diffuse Large B Cell Lymphoma].

PAX5 Interacts with RIP2 to Promote NF-κB Activation and Drug-Resistance of B-lymphoproliferative Disorders

The Expression and Clinical Significance of COX-2 and P-gp in B Cell Lymphoma

[Expression of the Transcription Factor PAX5 in Childhood Acute Leukemic Cells].

Expression of the Transcription Factor Pax5/Bsap in Childhood Acute Leukemia Cells and Haematological Tumor Cell Lines.

[Mutation and Expression of PAX5 Gene in Adult Acute Lymphoblastic Leukemia].

BCL-6,CD10 and BCL-2 Protein Expression in B-cell Non-Hodgkin's Lymphoma and Its Clinicopathologic Significance

[The Expression of CD19 in 210 Cases of Childhood Acute Leukemia and Its Significance].

Expression and Significance of LAT and CD99 in Precursor T Lymphoblastic Lymphoma

The expression and clinical relevance of PD-1, PD-L1, and TP63 in patients with diffuse large B-cell lymphoma.

Diagnostic Utility of the B-cell Lineage Markers CD20, CD79a, PAX5, and CD19 in Paraffin-embedded Tissues From Lymphoid Neoplasms

Significance of SHP-1 Expression in Benign Lesions of Lymphoid Tissues and Lymphomas

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia

Expression and Significance of Cyclin A and PCNA in B-cell Non-Hodgkin's Lymphoma

The Expression of SOX1 1, Cyclin D1, Cyclin D2 and Cyclin D3 in B-cell Lymphocytic Proliferative Diseases

[Analysis of Immunophenotype Characteristics in 109 Cases of B Lineage Chronic B Lymphoid Leukemia].

B-cell lymphoma/leukaemia 11B (BCL11B) expression status helps distinguish early T-cell precursor acute lymphoblastic leukaemia/lymphoma (ETP-ALL/LBL) from other subtypes of T-cell ALL/LBL

Expressions and Their Clinical Significances of E2F1, BIRC5 and PLK1 in B-cell Lymphoma